MedTrace Logo

DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients

NCT03033433 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2018-10-16

No results posted yet for this study

Summary

An Open-Label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as Add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients

Conditions

  • Type2 Diabetes

Interventions

DRUG

DCB-DM101

determination of optimal dose for Stage 2

Sponsors & Collaborators

  • VitNovo, Inc.

    lead INDUSTRY

Principal Investigators

  • Yi-Jen Hung, MD · Tri-Service General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-12-31
Completion
2018-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03033433 on ClinicalTrials.gov